Pancreatic Cancer Research

ResearcherOsaka City UniversityActive in the last 2 years

Kenjiro Kimura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9946-2624; OpenAlex author ID A5065897620. Sources: OpenAlex.

Their work

Papers
22 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 4 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 22

  1. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  2. A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreat… Co-author DOI 10.1038/s41598-024-61142-y↗
  3. [Devising a Surgical Approach Using the Intestinal Derotation Procedure for Locally Advanced Pancreatic Cancer]. Co-author PMID 39948948↗
  4. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… First author DOI 10.1002/ags3.12712↗
  5. Pancreaticoduodenectomy with celiac artery resection (PD-CAR) for unresctable locally advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-023-02860-1↗
  6. Cytoglobin attenuates pancreatic cancer growth via scavenging reactive oxygen species. Co-author DOI 10.1038/s41389-022-00389-4↗
  7. Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Co-author DOI 10.1097/md.0000000000032150↗
  8. Optimal Organ for Patient-derived Xenograft Model in Pancreatic Cancer and Microenvironment that Contributes to Success. First author DOI 10.21873/anticanres.15718↗
  9. Establishment of a Liver Transplant Patient-derived Tumor Xenograft (PDX) Model Using Cryopreserved Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.14234↗
  10. Pancreatic Cancer Cell Fraction Estimation in a DNA Sample. Co-author DOI 10.1159/000491637↗
  11. [A Case of Male Breast Cancer Suspected of Breast Metastasis from Pancreatic Cancer]. Co-author PMID 30692377↗
  12. Analysis of the origin of anaplastic pancreatic cancer and the mechanism of its dedifferentiation. First author DOI 10.1002/jhbp.429↗
  13. Preoperative predictors for early recurrence of resectable pancreatic cancer. First author DOI 10.1186/s12957-016-1078-z↗
  14. Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. First author DOI 10.1186/s12885-016-2297-y↗
  15. Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia. Co-author DOI 10.1371/journal.pone.0159912↗
  16. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresecta… First author DOI 10.1016/j.surg.2015.02.016↗
  17. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1186/1477-7819-12-360↗
  18. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. Co-author DOI 10.1186/1471-2407-13-392↗
  19. MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways. Co-author DOI 10.3892/ijo.2013.1760↗
  20. In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells. Co-author DOI 10.5754/hge13195↗
  21. [A case of locally advanced pancreatic cancer with hepatic artery invasion treated with neoadjuvant chemoradiotherapy]. First author PMID 24393948↗
  22. HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Co-author DOI 10.1159/000333825↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryosuke Amano · 16 shared papers, 2011–2023 · strength 1.16
  2. Kohei Nishio · 7 shared papers, 2014–2024 · strength 0.73
  3. Kosei Hirakawa · 13 shared papers, 2011–2018 · strength 0.67
  4. Hiroji Shinkawa · 4 shared papers, 2020–2024 · strength 0.59
  5. Ryota Tanaka · 4 shared papers, 2020–2024 · strength 0.59
  6. Takeaki Ishizawa · 3 shared papers, 2023–2024 · strength 0.53
  7. Masaichi Ohira · 8 shared papers, 2011–2020 · strength 0.46
  8. Sadaaki Yamazoe · 7 shared papers, 2014–2020 · strength 0.46
  9. Masakazu Yashiro · 5 shared papers, 2013–2022 · strength 0.37
  10. Sohei Satoi · 2 shared papers, 2023–2026 · strength 0.37
  11. Hiromitsu Hayashi · 2 shared papers, 2023–2026 · strength 0.37
  12. Hiroki Yamaue · 2 shared papers, 2023–2026 · strength 0.37
  13. Seiko Hirono · 2 shared papers, 2023–2026 · strength 0.37
  14. Shoji Kubo · 3 shared papers, 2020–2022 · strength 0.35
  15. Hideki Motobayashi · 1 shared paper, 2026 · strength 0.23
  16. Akimasa Nakao · 1 shared paper, 2026 · strength 0.23
  17. Masaaki Hidaka · 1 shared paper, 2026 · strength 0.23
  18. Keiko Kamei · 1 shared paper, 2026 · strength 0.23
  19. Yuji Kitahata · 1 shared paper, 2026 · strength 0.23
  20. Masafumi Nakamura · 1 shared paper, 2026 · strength 0.23
  21. Ryo Morimura · 1 shared paper, 2026 · strength 0.23
  22. Masayuki Sho · 1 shared paper, 2026 · strength 0.23
  23. Kenichiro Uemura · 1 shared paper, 2026 · strength 0.23
  24. Yuichi Nagakawa · 1 shared paper, 2026 · strength 0.23
  25. Yuko Mataki · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.